hotspot -WSS

hotspot

author：comprehensive 2025-09-27 22:47:23 - browse：568

LONDON — AstraZeneca said Tuesday it would acquire Fusion Pharmaceuticals in a deal worth more than $2 billion, picking up a company focused on the booming area of targeted radiation therapies for cancer.

AstraZeneca will pay $2 billion in cash upfront for Fusion, a price that at $21 a share is nearly double Fusion’s closing share price on Monday. If certain regulatory milestones are met, AstraZeneca will pay another $3 a share, or roughly $400 million.

Fusion specializes in developing radiopharmaceuticals, also known as radioconjugates or radioligands, which deliver radiation directly to tumors, guided by particular markers on cancer cells. The aim is not only to minimize the risk of damaging surrounding, healthy tissue, but also to reach tumors that traditional radiation can’t.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Chinese researcher claims birth of first gene

focus

WSS

Study: Spinal cord stimulation helps patients with paralysis walk again

Readout LOUD podcast, live from the STAT Breakthrough Summit East

CRISPR technology availability, affordability needs to be expanded

National associations that represent hospice owe an apology

Pregnancy ages women, but effects reverse after delivery

Health officials lay out plans to cope with respiratory virus season

knowledge

hotspot

Wikipedia

Moonlake's readout produced a cash windfall. Risks remain

Trans patients at the end of life deserve respect and dignity

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Pfizer, Moderna say biotech, pharma drug development is a sprint

Bright Health sells Medicare Advantage business to Molina

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Cancer, immunology, HIV research ensnared in fetal tissue politics

Moonlake's readout produced a cash windfall. Risks remain

Can U.S. cancer drug shortages be fixed?

focus

Pfizer, Moderna say biotech, pharma drug development is a sprint

Can U.S. cancer drug shortages be fixed?

Can U.S. cancer drug shortages be fixed?

Chinese researcher claims birth of first gene

How the drug

Trump to be booked at notorious Fulton County Jail at center of DOJ probe

focus

focus

Wikipedia

Wikipedia